atomoxetine 0.5 mg/kg/day

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Attention Deficit Hyperactivity Disorder

Drug Information

Target Indication

Attention Deficit Hyperactivity Disorder

Clinical Trial

Last updated: 3/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Related Pipeline

Growth Disorder

Type 1 Diabetes Mellitus

Obesity

Attention Deficit Hyperactivity Disorder

Urinary Stress Incontinence